Aydogdu Aydogan, Haymana Cem, Baskoy Kamil, Durukan Ali H, Ozgur Gokhan, Azal Omer
Department of Endocrinology and Metabolism, Gulhane School of Medicine, Ankara, Turkey.
Department of Ophthalmology, Gulhane School of Medicine, Ankara, Turkey.
J Res Med Sci. 2014 Jan;19(1):75-9.
We report a case of choroidal neovascularization (CNV) secondary to methylenetetrahydrofolate reductase (MTHFR) gene mutation in a 20-year-old male patient with hypopituitarism. Treatment with three consecutive injections of intravitreal ranibizumab (anti-vascular endothelial growth factor) resulted in significant improvement of the patient's vision and the appearance of the macula. A search of the literature produced no previously reported case of MTHFR gene mutation associated both CNV and possibly hypopituitarism. With hormone replacement therapy of hypopituitarism, acetyl salicylic acid 100 mg/day also was started. The patient was clinically stable both for CNV and other thromboembolic disorders over a 6-month follow-up and also 1-year follow-up period.
我们报告了一例20岁男性垂体功能减退患者继发于亚甲基四氢叶酸还原酶(MTHFR)基因突变的脉络膜新生血管(CNV)病例。连续三次玻璃体内注射雷珠单抗(抗血管内皮生长因子)治疗后,患者视力及黄斑外观有显著改善。检索文献未发现先前报道的与CNV以及可能的垂体功能减退相关的MTHFR基因突变病例。在对垂体功能减退进行激素替代治疗的同时,开始给予每天100毫克乙酰水杨酸治疗。在6个月随访期及1年随访期内,该患者的CNV及其他血栓栓塞性疾病在临床上均保持稳定。